Bio

Renaud Bonnet co-chairs Jones Day's global Private Equity Practice, and his practice areas include venture capital, private equity, M&A, and capital markets. He represents technology and life sciences companies, as well as the private equity and industrial investors that finance them, at every stage of development from entrepreneurial start-ups to multibillion dollar global corporations. He has acted as principal lawyer in a significant number of early to late-stage financing rounds, LBO and other M&A transactions, joint ventures, initial public offerings, rights issues, private placements, and tender offers. Renaud's recent experience includes representations of technology and life sciences companies Adocia, Advicenne, Ansys, Cellectis, Criteo, Devialet, EcoVadis, HRA Pharma, Ivalua, ManoMano, Mauna Kea Technologies, Nanobiotix, Planisware, Prodways, Sigfox, Talend, TxCell, Voltalia, and Voluntis. His recent investor-side representations include: Abingworth, Alven, Bain Capital Ventures, Bpifrance, Creadev, Danone Ventures, Elaia, Felix Capital, Goldman Sachs, Orange, Hi Inov, Idinvest, Illumina Ventures, Khazana, Seventure, Temasek, and Sofinnova. Transactions in which Renaud acted as lead lawyer include: representing the issuer and/or underwriters in more than 100 IPOs and follow-on offerings; the IPOs of Criteo, Cellectis, and Talend on Nasdaq; the tender offers on Completel, Wavecom, Assystem, and TxCell; the LBOs of HRA Pharma by Astorg and Goldman Sachs, Orolia by Eurazeo, A2Mac1 by Five Arrows, and Brico Privé by Florac; the sale of Novexel to AstraZeneca and Synthesio to Ipsos; the acquisition of French technology companies by Autodesk, Criteo, SAP, and Ansys; and the latest financing rounds of Devialet, Ivalua, ManoMano, and EcoVadis. Renaud was a member of the Consultative Commission on Issuers' Transactions and Financial Information of the French Financial Markets Authority (AMF) from 2017 to 2019.